MILLENDO THERAPEUTICS Revenue and Competitors
Estimated Revenue & Valuation
- MILLENDO THERAPEUTICS's estimated annual revenue is currently $310k per year.
- MILLENDO THERAPEUTICS's estimated revenue per employee is $77,500
- MILLENDO THERAPEUTICS's total funding is $116.5M.
Employee Data
- MILLENDO THERAPEUTICS has 4 Employees.
- MILLENDO THERAPEUTICS grew their employee count by -33% last year.
MILLENDO THERAPEUTICS's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Finance | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Interim General Counsel | Reveal Email/Phone |
MILLENDO THERAPEUTICS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.9M | 12 | 0% | N/A | N/A |
#2 | $3.2M | 41 | -56% | $31.2M | N/A |
#3 | $0.9M | 6 | 20% | N/A | N/A |
#4 | $2.2M | 29 | 93% | N/A | N/A |
#5 | $6.2M | 40 | 3% | N/A | N/A |
#6 | $5.4M | 35 | 35% | N/A | N/A |
#7 | $2M | 13 | 8% | N/A | N/A |
#8 | $0.6M | 4 | -20% | N/A | N/A |
#9 | $13M | 84 | -11% | N/A | N/A |
#10 | $4.2M | 27 | 4% | N/A | N/A |
What Is MILLENDO THERAPEUTICS?
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing's Syndrome (CS).
keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals
$116.5M
Total Funding
4
Number of Employees
$310k
Revenue (est)
-33%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MILLENDO THERAPEUTICS News
Millendo Therapeutics. Levo Therapeutics. Harmony Biosciences. Soleno Therapeutics. And many more. Prader-Willi Syndrome Therapies covered in...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is ...
ANN ARBOR, Mich.--(BUSINESS WIRE)--. Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company developing novel ...
Millendo Therapeutics, Inc. (MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan ...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints —Millendo Therapeutics, an Ann Arbor-based biopharmaceutical company developing treatments for rare diseases, has initiated a Phase 2b/3 clinical study investigating livoletide (AZP-531) in patients with Prader-Willi syndrome. Th ...
Other Companies in Ann Arbor
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.3M | 4 | N/A | N/A |
#2 | $0.7M | 4 | 33% | N/A |
#3 | $0.3M | 4 | 0% | N/A |
#4 | $0.3M | 4 | -60% | N/A |
#5 | $0.5M | 4 | -69% | N/A |